All In Biotech

Drug Trial Radar · NCT05657301

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Oct 16, 2023

Primary completion

Sep 2026

Study completion Sep 2027

Sponsor

Sponsor type
Industry
First posted
Dec 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

VAN-2201 is Phase I clinical trial to assess the safety and tolerability of KH631 in subjects with neovascular AMD. KH631 is gene therapy designed to deliver a protein which targets and blocks VEGF via an adeno-associated viral vector. The standard of care for patients with neovascular AMD are anti-VEGF treaments, which have demonstrated improvement in vision and reduction in fluid. A one time placement of a product which inhibits VEGF has the potential to reduce the patient burden of regular intraocular injections.

Conditions

  • Age-Related Macular Degeneration

Interventions

  • KH631Drug

    KH631: AAV vector containing a coding sequence for an anti-VEGF protein

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety (Type, Severity and Incidence of ocular and systemic AEs and SAEs)Time frame: 52 Weeks
  2. Best Corrected Visual AcuityTime frame: 52 Weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Kanghong Investigative Site

    Phoenix, Arizona

  • Kanghong Investigative Site

    Lemont, Illinois

  • Kanghong Investigative Site

    Boston, Massachusetts

  • Kanghong Investigative Site

    Reno, Nevada

  • Kanghong Investigative Site

    Cherry Hill, New Jersey

  • Kanghong Investigative Site

    Germantown, Tennessee

  • Kanghong Investigative Site

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.